Regulus Therapeutics
Acquired
Pioneering microRNA therapeutics for serious diseases
- Headquarters
- Carlsbad, California
- Employees
- 11–50
- Founded
- 2007
- Business Model
- B2B
- Website
- regulusrx.com
- Total Funding
- $120.0M
- Last Round
- $20.0M Series A
About
Regulus Therapeutics is a biopharmaceutical company founded in 2007 as a joint venture between Alnylam Pharmaceuticals and Ionis Pharmaceuticals. The company pioneered the development of oligonucleotide therapeutics that inhibit dysregulated microRNA targets. Its lead program, farabursen (RGLS8429), targeted ADPKD, the most common genetic cause of renal failure. In April 2025, Novartis agreed to acquire Regulus for up to $14 per share, valuing the deal at approximately $1.7 billion.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account